Boosting multiregional clinical trials (MRCT) in Asia through the establishment of the Japan-led network for clinical research, the ARO alliance for ASEAN & East Asia (ARISE)

被引：2

作者：

Sonoda, Miwa ^{[1
]}

Urbiztondo, Maria Ruriko Umano ^{[1
]}

Siburian, Marlinang Diarta ^{[1
]}

Kerdsakundee, Nattha ^{[1
]}

Muchanga, Sifa Marie Joelle ^{[1
]}

Iiyama, Tatsuo ^{[1
]}

机构：

[1] Natl Ctr Global Hlth & Med, Dept Int Trials, Tokyo, Japan

来源：

GLOBAL HEALTH & MEDICINE | 2022年 / 4卷 / 04期

关键词：

clinical research; clinical trial; global health; Asia;

D O I：

10.35772/ghm.2022.01007

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

There is an increasing demand for clinical research, and this demand has particularly increased during the novel coronavirus infection (COVID- 19) pandemic. In the light of these events, fostering international cooperation has become essential. The ARO Alliance for ASEAN & East Asia (ARISE) is a Japan-led international network for clinical research in Asia that was established to encourage and facilitate multiregional clinical trials. The Department of International Trials of the National Center for Global Health and Medicine (NCGM) launched ARISE in December 2021 to pursue efficacious, high-quality clinical research and ensure rapid responses to health emergencies, with the timely provision of new medicinal products to patients in Asia.

引用

页码：247 / 249

页数：3

共 2 条

[1] Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia
Noguchi, Atsushi
Hanaoka, Hideki
Uyama, Yoshiaki
[J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2022, 56 (03) : 523 - 529
[2] Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia
Atsushi Noguchi
Hideki Hanaoka
Yoshiaki Uyama
[J]. Therapeutic Innovation & Regulatory Science, 2022, 56 : 523 - 529

← 1 →